Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33801
Title: | Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis. | Austin Authors: | Reynolds, Gemma K;Sim, Beatrice;Spelman, Tim;Thomas, Ashmitha;Longhitano, Anthony;Anderson, Mary Ann;Thursky, Karin;Slavin, Monica;Teh, Benjamin W | Affiliation: | Dpartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Infectious Diseases, Austin Health, Melbourne, Victoria. National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Infectious Diseases Department of Infectious Diseases, Barwon Health, Melbourne, Victoria. Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria. |
Issue Date: | Dec-2023 | Date: | 2023 | Publication information: | Critical Reviews in Oncology/Hematology 2023-12; 192 | Abstract: | A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/33801 | DOI: | 10.1016/j.critrevonc.2023.104134 | ORCID: | Journal: | Critical Reviews in Oncology/Hematology | Start page: | 104134 | PubMed URL: | 37739146 | ISSN: | 1879-0461 | Type: | Journal Article | Subjects: | CAR-T Cellular therapies Infections Lymphoma Myeloma |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.